Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review
Research output: Contribution to journal › Review › Research › peer-review
As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.
Original language | English |
---|---|
Journal | Adverse Drug Reaction Bulletin |
Volume | 339 |
Issue number | 1 |
Pages (from-to) | 1315-1318 |
Number of pages | 4 |
ISSN | 0044-6394 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
ID: 344447603